CORRIGENDUM

DOI: 10.3892/ijo.2022.5313

The Pleckstrin and Sec7 domain-containing gene as a novel epigenetic modification marker in human gastric cancer and its clinical significance

XINJIANG ZHU, JIAN LIU, XIAOYANG XU, CHUNDONG ZHANG and DONGQIU DAI

Int J Oncol 46: 195-204, 2015; DOI: 10.3892/ijo.2014.2736

Subsequently to the publication of the above article, an interested reader drew to the authors' attention that a pair of panels in Fig. 6C appeared to contain overlapping data, such that the data, which were intended to show the results from experiments performed under different experimental conditions, may have been derived from the same original source. The authors have re-examined their original data, and have realized that this figure was assembled incorrectly; essentially, the data panel showing the results of the SGC7901-Si-NC experiment in Fig. 6C was incorporated incorrectly during the process of assembling this figure.

The corrected version of Fig. 6, showing all the correct data for Fig. 6C, is shown opposite. The authors confirm that this inadvertent error did not have any major impact on the conclusions reported in their paper, and are grateful to the Editor of *International Journal of Oncology* for allowing them this opportunity to publish a Corrigendum. Furthermore, the authors apologize to the readership for any inconvenience caused.



Figure 6. Migration and invasion enhancement of SGC7901 cells after knocking down PSD expression. (A) Evaluation of PSD expression after transfection with siRNA-PSD, using RT-PCR. (B) Wound healing assay of SGC7901 cells. Images were taken at 0, 12 and 24 h after the wound was made (x100). Cell migration was enhanced at 24 h after knocking down PSD. (C) Matrigel invasion assay showed that knocking down PSD in SGC7901 cells significantly increased cell invasiveness.expression were significantly lower in RACK1-sh group tissues compared with those in the two control groups (mean ± SD, $^{*}P<0.05$). (B) RACK1 silence could decrease the expression of RhoA and increase the expression of E-cadherin of OSCC *in vivo* (mean ± SD, $^{*}P<0.05$).